Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2025-12-25 @ 3:54 AM
NCT ID:
NCT00003202
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed stage IIIA or IIIB non-small cell lung cancer that is unicentric and inoperable, including the following cellular types:
* Squamous cell carcinoma
* Adenocarcinoma
* Bronchoalveolar carcinoma
* Large cell anaplastic carcinoma
* Non-small cell lung cancer not otherwise specified
* Tumors may be multifocal if all of disease is believed to be result of direct spread
* Disease must be fully accessible by radiotherapy ports for the entire prescribed dose
* No supraclavicular nodes or diffuse pleural involvement
* No contralateral hilar disease or an exudative, bloody, or cytologically malignant effusion
* Measurable disease required for phase II of this study
PATIENT CHARACTERISTICS:
Age:
* Any age
Performance status:
* ECOG 0-2
Life expectancy:
* At least 1 year
Hematopoietic:
* Granulocyte count at least 1,500/mm3
* Platelet count at least 100,000/mm3
* Hemoglobin greater than 10 g/dL
Hepatic:
* Bilirubin no greater than 2.0 mg/dL
Renal:
* BUN no greater than 1.5 times normal
* Creatinine no greater than 1.5 times normal
Pulmonary:
* FEV1 no greater than 1 liter except if tumor has negatively impacted
* pulmonary function
Other:
* No other serious medical or psychiatric illness
* No prior lung cancer except if free of disease for more than 3 years
* No other prior malignancy except nonmelanoma skin cancer or if free of
* disease for more than 1 year
* Not pregnant or nursing
* Negative pregnancy test
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* No prior thoracic radiotherapy
* Concurrent radiotherapy to other anatomic sites allowed
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
120 Years
Study:
NCT00003202
Study Brief:
Protocol Section:
NCT00003202